Objectives: To describe the multidisciplinary assessment of patent foramen ovale (PFO) with substantial right-to-left shunting (RLS) and medium-term follow-up after PFO closure for stroke or transient ischemic attack (TIA).
| INTRODUCTION
In recent years, transcatheter device closure of PFO has been used as a treatment option for the prevention of recurrent cryptogenic stroke or TIA. While PFO is noted in up to 25% of individuals, 1,2 25% of all ischemic strokes are cryptogenic, 3 and PFO presents in 40-50% of cryptogenic stroke patients, 4, 5 suggesting that the passage of a thrombus from the right to the left atrium across the PFO may be the causative mechanism. [6] [7] [8] Although several studies have demonstrated the safety and efficacy of transcatheter PFO closure, 9 the results of a series of RCTs showed that, compared with medical treatment, PFO closure did not show an obvious superiority. [10] [11] [12] The debate regarding which type of cryptogenic stroke or TIA requires further intervention has recently been a hot topic in the field. Significant differences between the prevention of cryptogenic stroke or TIA recurrence and medical treatment have not been observed. This may be because many patients included in the study had a PFO in conjunction with cryptogenic stroke or TIA, however, the PFO was not the primary cause of the cryptogenic stroke or TIA. Therefore, the appropriate multidisciplinary specialist pre-procedural assessment appears to be especially important. Only by screening out the true "pathological"
PFO cases can the superiority of percutaneous PFO closure be determined. The long-term results of the RESPECT trial, which was presented at the TCT conference in 2016, also confirmed this point.
The main difference between RESPECT and the other RCTs was that RESPECT recruited more relevant patients with substantial RLS. The long-term results of RESPECT support the hypothesis that PFO closure prevented PFO related recurrent strokes, while PFO closure could not prevent recurrent strokes from non-PFO related causes.
Strictly speaking, the patients included in the CLOSURE I and PC trials had cryptogenic stroke or TIA with a PFO, but the PFO was not necessarily the cause of the cryptogenic stroke or TIA.
This study aims to describe the multidisciplinary assessment of patients with PFO and substantial RLS and to examine the procedural success and medium-term outcomes of PFO closure within the First Chiari's network.
The severity of the shunt is a subjective assessment performed by cTTE and/or cTCD. Agitated saline was used as the contrast agent, which consisted of 8 ml of saline solution, 1 ml of air, and 1 ml of blood from the patients. Contrast agent was injected into the left cubital vein as a bolus. When using cTTE, the apical four-chamber view was generally selected. The presence of RLS was confirmed when micro bubbles (MBs) were seen in the left atrium within the first 3 cardiac cycles after contrast appearance in the right atrium during normal respiration or the Valsalva maneuver. According to Li Yue, etc., 16 the severity of RLS was semi-quantified into a four-level scale, and we defined substantial RLS >30 MBs.
According to current standard, 17 cTCD with a TCD monitoring device (DWL MultidopX, ScanMed Medical, Gloucestershire, UK)
can also be used to identify the degree of RLS. Both middle cerebral arteries were simultaneously monitored through the temporal window using 2 MHz probes. The contrast agent was used as of RLS was semi-quantified into a four-level scale, and we defined substantial RLS as shower or curtain HITS.
| PFO closure
Antibiotic Heparin was administered according to the patient's body weight (80-100IU/kg). All patients were investigated for early residual shunting and the presence of pericardial effusion using TTE within 24 hours following the procedure. After the procedure, all patients were treated with low-molecular-weight heparin at 10U/(kg · h) for 48 hours, aspirin 100 mg/day for 6 months, and clopidogrel 50-75 mg/day for 3 months following device implantation.
| Follow-up
All patients were followed at 1, 3, 6, and 12 months after device implantation and then yearly thereafter. Holter monitoring and TTE were performed to confirm the presence or absence of atrial fibrillation and device embolization. cTTE was followed up at 3 months after the procedure to observe residual RLS. If there was no residual RLS, cTTE examination was not required in future follow-up exams. If the RLS remained, cTTE examination was performed at follow-up exams until the RLS was no longer observed. All patients were followed after device implantation through questionnaires by phone calls or office visits with cardiovascular and neurological specialists. 
| Statistical analysis
Data analysis was performed using SPSS version 12.0. 
| Procedural characteristics
The Amplatzer PFO occluder was used in 69 cases (31.5%), and the Cardi-O-fix PFO occluder was used in 150 cases (68.5%). Local anesthesia was used in all 219 cases (100%). The mean procedure time was 24.7 ± 6.8 minutes. The mean fluoroscopy time was 3.4 ± 0.9 minutes ( Table 2) .
Technical success was defined as the delivery and release of the device and was achieved in all 219 patients (100%).
Procedural success, defined as implantation without in-hospital serious adverse events (SAEs), was also achieved in all 219 patients (100%). In four patients undergoing closure using the 
| Follow-up
Early residual shunting was visible on the color flow Doppler in nine patients (4.1%) during TTE imaging performed the day after device implantation. Residual RLS was detected by cTTE in 3 patients (1.4%) at 180 days after the procedure; the median time to the follow-up echocardiography was 154.5 ± 35.7 days. Patients with cryptogenic stroke or TIA were followed for a mean of 2.0 ± 0.7 years to assess for recurrent stroke, TIA, atrial fibrillation and death. One patient died during the study period because of lung cancer.
The rate of recurrent stroke or TIA in our cohort was 0.457 per 100 patient-years (Table 3) 
| DISCUSSION
Although PFO combined with cryptogenic stroke or TIA was widely investigated in previous observational studies and RCTs, the relevant reports for the degree of RLS are rare, especially patients with PFO and substantial RLS. Previously, a considerable number of patients with minimal or moderate RLS have been included in studies. Sorensen described the degrees of RLS in 5 studies, 18 it was surprising to find that in the PICSS and SPARC studies, the proportion of patients with less than 10 MBs had reached 59 and 75%, respectively. In the CLOSURE I, RESPECT and PC trials, the proportion of patients with less than 25 MBs (minimal to moderate shunts) were 82, 39, and 77%, respectively. However, in the U.S. State of Utah UPSG center, Sorensen analyzed 2,700 cases of patients with PFO occlusion and found that 99% had substantial RLS. In more than 700 cases of PFO closure at the First Affiliated Hospital of Xi'an Jiaotong University, the vast majority have been diagnosed with substantial RLS. Whether this was because too many minor RLS cases were included, to a certain extent, the results of the above RCTs were not clear. Of the three RCTs, only the RESPECT trial had positive results; however, since it had included some mild to moderate RLS patients, some limitations also exist in that study. Nevertheless, the RESPECT trial identified that the patients with substantial RLS experienced the greatest benefit.
Therefore, the present study was conducted to specifically investigate the recurrence risk of stroke or TIA after PFO closure by multidisciplinary assessment in patients with substantial RLS, as determined by cTCD and/or cTTE.
Similar to the previous studies, 19, 20 technical success and procedural success were achieved in all 219 patients, confirming the safety of the transcatheter closure of PFO procedure. Meanwhile, Procedural success, n (%) 219 (100%)
Early shunt, n (%) 9 (4.1%)
Procedural complication, n (%) 7 (3.2%)
Arteriovenous fistula 2
False aneurysm, 2 Hematoma 1
Pericardial effusion 2
Residual RLS, n (%) 3 (1.4%) PFO, patent foramen ovale; RLS, right-to-left shunting. Chiari's network, n (%) 5 (2.3%)
annual incidence of recurrent neurological events in this study was low (0.457%), which was lower than that reported in previous RCTs. [10] [11] [12] The rate of recurrent stroke was 0.66 and 0.5% in the RESPECT and PC trials, respectively; the mean follow-up duration was 2.8 years and 4.1 in the RESPECT and PC trials, respectively. Altogether, the previous RCTs including CLOSURE I, RESPECT, and PC trials showed that the recurrence rates of stroke or TIA were higher than the rates reported in this study. The reason for this may be due to experimental design flaws and the high incidence of complications from the occluders used in the previous studies. In addition to these reasons, one of the most important reasons may be the inclusion of patients with minimal or moderate RLS in these studies. In contrast, all of the patients included in the present study had substantial RLS, which was confirmed by cTCD and/or cTTE.
In addition, the collaboration between cardiologists and neurol- Serious complications directly associated with the procedure were rare in our study group. Atrial fibrillation after the procedure was paroxysmal and all cases were resolved spontaneously or by pharmacologic conversion back to sinus rhythm. In summary, transcatheter closure of PFO appears to be safe, effective, and rarely associated with serious complications.
| Limitations of the study
In our study, the follow-up time was only 2.0 ± 0.7 years. Although the recurrence of embolization usually appears within this time frame, the results may be affected. Furthermore, the limitations of this study include the retrospective design of our study, small sample size, and not performing TEE in all of the patients before PFO closure.
| CONCLUSION
Although the role of PFO in the etiology of cryptogenic stroke and TIA is still controversial, a select patient group seems to benefit from PFO closure, particularly the patients with substantial RLS. In this multidisciplinary pre-procedural assessment, the transcatheter closure of PFO was found to be safe and effective. Excellent long-term results with low incidence of recurrent events may be achieved by collaborating with stroke neurologists to exclude alternate mechanisms of cerebral ischemia. Cerebral ischemia after PFO closure may reflect additional risk factors unrelated to paradoxical embolism. Although the transcatheter procedure is safe and is associated with a low rate of early complications, careful selection of candidates for PFO closure is essential. 
